30 April 2025 in European Journal of Neurology
Background: Postural instability and gait difficulties are key symptoms of Parkinson's disease (PD), elevating the risk of falls substantially. Falls afflict 35% to 90% of PD patients, representing a major challenge in managing the condition. Accurate prediction of fall risk and identification of contributing factors are essential for timely interventions.Objectives: Our objective was to develop and validate a machine learning (ML) algorithm across multiple centers in Italy to accurately forecast fall risk and identify related factors using routinely collected clinical data.Methods: Patient data from two Italian centers (N = 251) were divided into a training cohort (N = 164) for ML model development and a validation cohort (N = 87). External validation was conducted on a subset of PPMI study patients (N = 65). We compared the performance of logistic regression (LR) and Support Vector Classifier (SVC) models trained on clinical data. The Shapley Additive exPlanations (SHAP) method was employed to examine the predictive power of individual variables.Results: In the training set, SVC outperformed LR slightly (AUC: LR = 0.779 ± 0.054, SVC = 0.792 ± 0.056). However, LR demonstrated better prediction accuracy in both internal (AUC: LR = 0.753, SVC = 0.733) and external validation cohorts (AUC: LR = 0.714, SVC = 0.676). SHAP analysis on the LR model revealed associations between fall risk and both motor and non‐motor variables.Conclusions: ML‐based models effectively estimate fall risk across different clinical centers, enabling tailored interventions to enhance PD patients' quality of life. Challenges persist in predicting falls in US‐based patients due to demographic and healthcare system differences.
30 April 2024 in Parkinsonism & Related Disorders
28 November 2025 in European Journal of Neurology
Background: Predicting prognosis in people with multiple sclerosis (pwMS) at early disease stages still remains an unmet need. Machine learning (ML) strategies demonstrated good reliability when applied for prediction in medicine. This study aimed at developing a predictive algorithm comparing different ML approaches, by using routine demographic, clinical and radiological data from a large multicentric cohort of newly diagnosed pwMS. Methods: Demographic, clinical, radiological and biochemical data were retrospectively collected at three Italian MS centers at baseline and four timepoints thereafter (6, 12, 24, and 36 months). Data from the first evaluation and subsequent 2‐year follow‐up were analyzed, comparing different ML models (Random Forest, Extra Trees, XGBoost, Logistic Regression and Support Vector Classifier) to predict progression independent of relapse activity (PIRA) at year 3. To understand how features impacted the selected model's output, a ML explainability analysis was performed on the whole cohort and on specific subsets of patients, those aged under 45 and those NEDA‐3 at the 2‐year follow‐up. Results: Data from 719 pwMS (age 34.6 ± 11.2 years); female sex 501 (70%) were analyzed. Ninety‐two pwMS (13%) developed PIRA at year 3. Random Forest achieved the highest score, with a test set area under the ROC curve (AUC) of 0.75 ± 0.06. Features with the highest predictive impact were Expanded Disability Status Scale at 24 months, age at symptom onset and disease duration at baseline. Conclusion: Our results showed the feasibility of applying ML techniques to predict short‐term PIRA in newly diagnosed pwMS by using routine clinical practice data, paving the way for tailored and personalized approaches.
6 January 2025 in Brain Stimulation
11 February 2025 in European Journal of Neurology
Background: Parkinson's disease (PD) treatments, such as apomorphine (APO) and levodopa–carbidopa intestinal gel (LCIG), represent advanced therapeutic options for managing motor symptoms. However, clear selection criteria and well‐defined cognitive outcomes are lacking. This systematic review specifically aimed to address these gaps by assessing the cognitive impact of APO and LCIG in PD patients.Methods: A systematic review was conducted following PRISMA guidelines, with searches in PubMed, Web of Science, Scopus, and Embase. Two authors screened studies based on key inclusion criteria, including at least two cognitive tests, and a follow‐up of 6 months or more. The risk of bias was evaluated using the Newcastle–Ottawa Scale (NOS).Results: Fifteen studies were identified (7 APO and 8 LCIG). APO generally preserved cognitive function over a 12‐month follow‐up, with some decreases in visuospatial memory and executive functions. LCIG, with a 28‐month follow‐up, showed more extensive cognitive decline, particularly in patients with pre‐existing impairments. Variability in cognitive tests made direct comparisons difficult.Discussion: APO may have a more favorable cognitive profile than LCIG. However, differences in follow‐up duration, moderate risk of bias, and inconsistent cognitive assessments warrant cautious interpretation. Improved patient selection and comprehensive cognitive evaluations are recommended for future practice.
4 July 2025 in Clinical Parkinsonism & Related Disorders
Cognitive impairment is a major non-motor complication of Parkinson’s disease (PD). GBA mutations are associated with an increased risk, with PD-GBA+ patients typically showing earlier disease onset and faster cognitive decline. However, the specific cognitive phenotype of these patients remains unclear. To provide a detailed neuropsychological profile of PD-GBA+ patients compared to PD-GBA− patients. Data from 18 PD-GBA+ and 68 PD-GBA− patients were retrospectively analyzed. All participants underwent comprehensive neurological evaluations of motor and non-motor symptoms, along with a Level II neuropsychological assessment based on the MDS criteria for mild cognitive impairment (MCI). Patients with dementia were excluded. PD-GBA+ patients showed significantly lower cognitive performance, particularly on the RAVLT immediate recall (RAVLT-IR, p < 0.001) and delayed recall (RAVLT-DR, p = 0.002). All PD-GBA+ patients exhibited an amnestic multi-domain MCI phenotype. In contrast, the PD-GBA− group predominantly showed a non-amnestic single-domain MCI, characterized by a dysexecutive profile. Additionally, PD-GBA+ patients had a higher prevalence of freezing of gait (p < 0.001), right-sided motor symptom lateralization (p = 0.011), and REM sleep behavior disorder (p = 0.006). PD-GBA+ patients exhibit a distinctive cognitive phenotype, already evident in the early stages of the disease. These results highlight the added value of Level II neuropsychological assessment in accurately characterizing the clinical phenotype and identifying patients at higher risk of developing dementia. Early cognitive profiling may thus contribute to more targeted monitoring and personalized therapeutic strategies.